Trade Editas Medicine (EDIT) shares | Commission-free on Freetrade

Editas Medicine$EDIT • Gene editing

$1.51

+19.79%(+$0.25)in the last month

The US market is currently closed. It will re-open at 13:30 tomorrow.

Stats

Get access to key stats

US Market

About Editas Medicine Inc

This firm aims to develop therapies based on CRISPR gene-editing technology.

Health

Sector

Costs and charges

Analyst ratings & estimates

Advanced stock fundamentals

Freetrade is your gateway to commission-free investing. Join over 1.6 million users using the Best online trading platform, as voted at the British Bank Awards for six years running.

Accounts

Stocks and Shares ISA Personal Pension General Investment

Customer Support

Help Community Complaints Here for you Investment risk

Resources

Dictionary Compare Plans

Company

About Careers

Legal

T&Cs Privacy policy Cookie policy Order execution policy

Conflicts of interest Execution venues Keeping your money safe MIFIDPRU disclosures

Freetrade does not provide investment advice and individual investors should make their own decisions or seek independent advice. The value of investments can go down as well as up and you may receive back less than your original investment. Past performance is not a reliable indicator of future returns. Freetrade is a trading name of Freetrade Limited, which is a member firm of the London Stock Exchange and is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales (no. 09797821).